Sarah Brockbank, Strategy Leader – Complex Medicines at Medicines Discovery Catapult, shares insight into a new regulatory roadmap created by the UK’s Intracellular Drug Delivery Centre (IDDC).
President Trump’s “Liberation Day” announcement on April 2 could disrupt biotech, with BIO’s survey showing 90% of U.S. biotech firms relying on imports for FDA-approved products. In addition, news from the mRNA vaccine progress, new lab spaces and Innovate UK’s new leadership.
Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise.
Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
As 2024 comes to a close, we’re proud to reflect on a year of championing the life sciences sector, from driving impactful policy changes to fostering connections across the UK and beyond. Dive into our key achievements, events, and milestones that shaped the year and set the stage for an exciting 2025.
When comparing the UK’s RNA manufacturing capability now, to that of before COVID-19, it is obvious that great advancements have been made. Abby Clark, Senior Manufacturing Programme Executive at the BIA, reflects on the past (nearly) five years and highlights recent work in the area.
Quotient Sciences announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), a modular, integrated, and automated RNA-micro factory which enables the end-to-end production of various RNA-based products.
The government's plan to put life sciences up in lights this Sunday ahead of the International investment Summit was somewhat overtaken by the news of the reorganisation of Keir Starmer's Number 10 team which dominated headlines. Nevertheless, it's been a busy week of announcements affecting our sector.
This report from the BIA, alongside CPI and Cytiva, highlights the critical role the UK is playing in the field of mRNA research, outlining the opportunities the technology presents, in addition to the challenges which still have to be overcome.
With the Prime Minister calling a snap election set for 4 July, the BIA’s attention has turned to preparing for the next government. Meanwhile, Parliament Day, our flagship day of parliamentary engagement, has been postponed to the autumn. Official engagements with civil servants have also been restricted in accordance with the pre-election period of sensitivity.
With a general election widely expected to be called later this year, the BIA’s long-established relationships with senior parliamentarians have been of particular importance this quarter. From launching the Labour Party’s Life Science Sector Strategy in Stevenage in January to hosting Science Minister Andrew Griffith MP at our Gala Dinner, we continue to represent the sector at the highest levels.
The BioIndustry Association (BIA) continued to represent the innovative life science and biotech sector to Ministers and senior policymakers between July and October 2023.
mRNA Revolution: A New Generation of Medicine explains how the UK will lead the way in developing and delivering next-generation mRNA medicines for a wide range of diseases, beyond just COVID-19.